DexecadotrilAlternative Names: Retorphan
Latest Information Update: 26 Nov 2015
At a glance
- Originator Bioprojet
- Class Analgesics; Antidiarrhoeals
- Mechanism of Action Neprilysin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal disorders
Most Recent Events
- 26 Nov 2015 Phase III development is ongoing in France